Ontology type: schema:ScholarlyArticle
2008-03-29
AUTHORSReiki Nishimura, Nobuyuki Arima
ABSTRACTBackgroundBreast cancer is characterized by hormone dependency, and endocrine therapy is a key treatment in breast cancer. Recently, targeted therapies such as Trastuzumab treatment for HER2-positive breast cancer has been important. Triple-negative (TN) breast cancer is characterized by lack of expression of estrogen receptor (ER) and progesterone receptor (PgR), and the absence of HER2 protein overexpression, and so there is no targeted therapy for this subtype. In this study, we examined the biological and prognostic characteristics in TN breast cancer.Patients and methodsBetween January 1998 and September 2006, 1,552 patients with primary breast cancer were investigated retrospectively in this study and ER, PgR and HER2 status were evaluated in all cases. Furthermore, p53 overexpression and Ki67 values were examined immunohistochemically.ResultsPatient distribution according to ER, PgR or HER2 status was as follows: ER and PgR positive: 57.9%, and ER and PgR negative: 25.1%. With regards to the HER2 status, HER2 positive was 23.3%, and triple negative (TN) was 14.0%. TN breast cancer has a high proliferation rate, high nuclear grade and frequent p53 overexpression. Patients with TN tumors had a significantly poorer disease-free survival (DFS) than those with non-TN tumors. After recurrence the overall survival (OS) rate in TN cases was significantly lower than that of the non-TN cases. Multivariate analysis revealed that TN was a significant factor for DFS and OS after recurrence.ConclusionTN breast cancer is a rare subtype with a high proliferation rate and a high nuclear grade, p53 overexpression, and lower DFS/OS. To improve the prognosis of TN breast cancer, a new effective strategy needs to be developed. More... »
PAGES303-308
http://scigraph.springernature.com/pub.10.1007/s12282-008-0042-3
DOIhttp://dx.doi.org/10.1007/s12282-008-0042-3
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1000535344
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/18369692
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Biomarkers, Tumor",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Breast Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Cell Proliferation",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Immunoenzyme Techniques",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neoplasm Staging",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Phenotype",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prognosis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Receptor, ErbB-2",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Receptors, Estrogen",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Receptors, Progesterone",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Retrospective Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Survival Rate",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Tumor Suppressor Protein p53",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan",
"id": "http://www.grid.ac/institutes/grid.415532.4",
"name": [
"Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan"
],
"type": "Organization"
},
"familyName": "Nishimura",
"givenName": "Reiki",
"id": "sg:person.013173055502.44",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013173055502.44"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan",
"id": "http://www.grid.ac/institutes/grid.415532.4",
"name": [
"Department of Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan"
],
"type": "Organization"
},
"familyName": "Arima",
"givenName": "Nobuyuki",
"id": "sg:person.016542450374.76",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016542450374.76"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/35021093",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1033846543",
"https://doi.org/10.1038/35021093"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00428-005-0010-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1048189318",
"https://doi.org/10.1007/s00428-005-0010-7"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10147-006-0601-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1001769831",
"https://doi.org/10.1007/s10147-006-0601-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.2325/jbcs.13.232",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1018645053",
"https://doi.org/10.2325/jbcs.13.232"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf02967579",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1049185654",
"https://doi.org/10.1007/bf02967579"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12282-007-0014-z",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017336968",
"https://doi.org/10.1007/s12282-007-0014-z"
],
"type": "CreativeWork"
}
],
"datePublished": "2008-03-29",
"datePublishedReg": "2008-03-29",
"description": "BackgroundBreast cancer is characterized by hormone dependency, and endocrine therapy is a key treatment in breast cancer. Recently, targeted therapies such as Trastuzumab treatment for HER2-positive breast cancer has been important. Triple-negative (TN) breast cancer is characterized by lack of expression of estrogen receptor (ER) and progesterone receptor (PgR), and the absence of HER2 protein overexpression, and so there is no targeted therapy for this subtype. In this study, we examined the biological and prognostic characteristics in TN breast cancer.Patients and methodsBetween January 1998 and September 2006, 1,552 patients with primary breast cancer were investigated retrospectively in this study and ER, PgR and HER2 status were evaluated in all cases. Furthermore, p53 overexpression and Ki67 values were examined immunohistochemically.ResultsPatient distribution according to ER, PgR or HER2 status was as follows: ER and PgR positive: 57.9%, and ER and PgR negative: 25.1%. With regards to the HER2 status, HER2 positive was 23.3%, and triple negative (TN) was 14.0%. TN breast cancer has a high proliferation rate, high nuclear grade and frequent p53 overexpression. Patients with TN tumors had a significantly poorer disease-free survival (DFS) than those with non-TN tumors. After recurrence the overall survival (OS) rate in TN cases was significantly lower than that of the non-TN cases. Multivariate analysis revealed that TN was a significant factor for DFS and OS after recurrence.ConclusionTN breast cancer is a rare subtype with a high proliferation rate and a high nuclear grade, p53 overexpression, and lower DFS/OS. To improve the prognosis of TN breast cancer, a new effective strategy needs to be developed.",
"genre": "article",
"id": "sg:pub.10.1007/s12282-008-0042-3",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1021080",
"issn": [
"1340-6868",
"1880-4233"
],
"name": "Breast Cancer",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "4",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "15"
}
],
"keywords": [
"disease-free survival",
"TN breast cancer",
"high nuclear grade",
"breast cancer",
"estrogen receptor",
"HER2 status",
"p53 overexpression",
"nuclear grade",
"high proliferation rate",
"HER2-positive breast cancer",
"poor disease-free survival",
"triple-negative breast cancer",
"non-TN tumors",
"overall survival rate",
"primary breast cancer",
"HER2 protein overexpression",
"frequent p53 overexpression",
"proliferation rate",
"endocrine therapy",
"prognostic factors",
"trastuzumab treatment",
"prognostic characteristics",
"rare subtype",
"hormone dependency",
"progesterone receptor",
"TN tumors",
"BackgroundBreast cancer",
"targeted therapy",
"Ki67 values",
"lack of expression",
"key treatment",
"survival rate",
"TN cases",
"multivariate analysis",
"cancer",
"patients",
"ResultsPatient distribution",
"therapy",
"protein overexpression",
"recurrence",
"new effective strategy",
"PgR",
"tumors",
"subtypes",
"receptors",
"overexpression",
"treatment",
"status",
"effective strategy",
"significant factor",
"OS",
"grade",
"prognosis",
"HER2",
"cases",
"survival",
"rate",
"factors",
"study",
"expression",
"absence",
"lack",
"regard",
"strategies",
"analysis",
"characteristics",
"values",
"distribution",
"dependency",
"TN"
],
"name": "Is triple negative a prognostic factor in breast cancer?",
"pagination": "303-308",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1000535344"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s12282-008-0042-3"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"18369692"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s12282-008-0042-3",
"https://app.dimensions.ai/details/publication/pub.1000535344"
],
"sdDataset": "articles",
"sdDatePublished": "2022-06-01T22:07",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_457.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s12282-008-0042-3"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12282-008-0042-3'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12282-008-0042-3'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12282-008-0042-3'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12282-008-0042-3'
This table displays all metadata directly associated to this object as RDF triples.
249 TRIPLES
22 PREDICATES
123 URIs
109 LITERALS
28 BLANK NODES